A non-cholinergic neuronal loss in the pedunculopontine nucleus of toxin-evoked Parkinsonian rats

Experimental Neurology

Volumn 248, Issue , 2013, Pages 213-223

  Pienaar, Ilse S ^a   van de Berg, Wilma ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Cholinergic; Non cholinergic; Parkinson's disease; Pedunculopontine nucleus; Stereology

Indexed keywords

NEURON SPECIFIC NUCLEAR PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN NERVE CELL; BRAIN REGION; BRAIN TISSUE; CELL COUNT; CELL DENSITY; CELL LOSS; CELLULAR DISTRIBUTION; CHOLINERGIC NERVE CELL; CONTROLLED STUDY; DOPAMINERGIC NERVE CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PARKINSONISM; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; PRIORITY JOURNAL; RAT; STEREOLOGY; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA;

Α-SYNUCLEIN; (+); 1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; 4′,6-DIAMIDINO-2-PHENYLINDOLE; 6-HYDROXYDOPAMINE; 6-OHDA; ABC; AVIDIN-BIOTIN-COMPLEX; CCD; CFV; CHARGE-COUPLED DEVICE; CHOLINERGIC; CRESYL FAST VIOLET; DA; DAB; DAPI; DBS; DEEP-BRAIN STIMULATION; DIAMINOBENZIDINE DIHYDROCHLORIDE; DOPAMINE; ETHANOL; ETOH; HUC/D; HUMAN NEURONAL PROTEIN; IMMUNOPOSITIVE; LATERODORSAL TEGMENTAL NUCLEUS; LDTG; MPTP; NDS; NEUN; NEURONAL-SPECIFIC NUCLEAR PROTEIN; NON-CHOLINERGIC; NORMAL DONKEY SERUM; PARAFORMALDEHYDE; PARKINSON'S DISEASE; PD; PEDUNCULOPONTINE NUCLEUS; PFA; PPN; RAPID EYE MOVEMENT; REM; ROOM TEMPERATURE; RT; SNCA [PROTEIN]; SNPC; SNR; STEREOLOGY; STN; SUBSTANTIA NIGRA PARS COMPACTA; SUBSTANTIA NIGRA PARS RETICULATA; SUBTHALAMIC NUCLEUS; TH; TYROSINE HYDROXYLASE;

ACETYLCHOLINE; ANIMALS; ANTIGENS, NUCLEAR; CELL DEATH; CHOLINERGIC NEURONS; MALE; NERVE TISSUE PROTEINS; NEURONS; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; PEDUNCULOPONTINE TEGMENTAL NUCLEUS; RATS; RATS, SPRAGUE-DAWLEY; SUBSTANTIA NIGRA;

EID: 84880163902     PISSN: 00144886     EISSN: 10902430     Source Type: Journal    
DOI: 10.1016/j.expneurol.2013.06.008     Document Type: Article

References (79)

1. Abercrombie M. Estimation of nuclear population from microtome sections. Anat. Res. 1946, 94:239-247.
2. Alderson H.L., Latimer M.P., Winn P.A. Functional dissociation of the anterior and posterior pedunculopontine tegmental nucleus: excitotoxic lesions have differential effects on locomotion and the response to nicotine. Brain Struct. Funct. 2008, 3:247-245.
3. Ambrosi G., Armentero M.T., Levandis G., Bramanti P., Nappi G., Blandini F. Effects of early and delayed treatment with an mGluR5 antagonist on motor impairment, nigrostriatal damage and neuroinflammation in a rodent model of Parkinson's disease. Brain Res. Bull. 2010, 82:29-38.
4. Ansorg A., Witte O.W., Urbach A. Age-dependent kinetics of dentate gyrus neurogenesis in the absence of cyclin D2. BMC Neurosci. 2012, 13:46.
5. 2O PET study. Hum. Brain Mapp. 2009, 30:3901-3909.
6. Baquet Z.C., Williams D., Brody J., Smeyne R.J. A comparison of model-based (2D) and design-based (3D) stereological methods for estimating cell number in the substantia nigra pars compacta (SNpc) of the C57BL/6J mouse. Neuroscience 2009, 161:1082-1090.
7. Bevan M.D., Bolam J.P. Cholinergic, GABAergic, and glutamate-enriched inputs from the mesopontine tegmentum to the subthalamic nucleus in the rat. J. Neurosci. 1995, 15:7105-7120.
8. Bohnen N.I., Albin R.L. The cholinergic system and Parkinson's disease. Behav. Brain Res. 2011, 221:564-573.
9. Bury A.G., Pienaar I.S. Behavioral testing regimens in genetic-based animal models of Parkinson's disease: cogencies and caveats. Neurosci. Biobehav. Rev. 2013, 37:846-859.
10. Charara A., Smith Y., Parent A. Glutamatergic inputs from the pedunculopontine nucleus to midbrain dopaminergic neurons in primates: phaseolus vulgaris-leucoagglutinin anterograde labeling combined with post-embedding glutamate and GABA immunohistochemistry. J. Comp. Neurol. 1996, 364:254-266.
11. Chu Y., Morfini G.A., Langhamer L.B., He Y., Brady S.T., Kordower J.H. Alteration in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain 2012, 135:2058-2073.
12. Clements J.R., Grant S. Glutamate-like immunoreactivity in neurons of the laterodorsal tegmental and pedunculopontine nuclei in the rat. Neurosci. Lett. 1990, 120:70-73.
13. Côté P.Y., Parent A. Calbindin D-28k and choline acetyltransferase are expressed by different neuronal populations in pedunculopontine nucleus but not in nucleus basalis in the squirrel monkey. Brain Res. 1992, 593:245-252.
14. Datta S., Siwek D.F. Single cell activity patterns of pedunculopontine tegmentum neurons across the sleep-wake cycle in the freely moving rats. J. Neurosci. Res. 2002, 70:611-621.
15. Filion M., Tremblay L. Abnormal spontaneous activity of globus pallidus neurons in monkeys with MPTP-induced Parkinsonism. Brain Res. 1991, 547:142-151.
16. Ford B., Holmes C.J., Mainville L., Jones B.E. GABAergic neurons in the rat pontomesencephalic tegmentum: co-distribution with cholinergic and other tegmental neurons projecting to the posterior lateral hypothalamus. J. Comp. Neurol. 1995, 363:177-196.
17. Fortin M., Parent A. Calretinin-immunoreactive neurons in primate pedunculopontine and laterodorsal tegmental nuclei. Neuroscience 1999, 88:535-547.
18. Gai W.P., Halliday G.M., Blumbergs P.C., Geffen L.B., Blessing W.W. Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 1991, 114:2253-2267.
19. Garcia-Rill E. The pedunculopontine nucleus. Prog. Neurobiol. 1991, 36:363-389.
20. Grofova I., Zhou M. Nigral innervations of cholinergic and glutamatergic cells in the rat mesopontine tegmentum: light and electron microscopic anterograde tracing and immunohistochemical studies. J. Comp. Neurol. 1998, 395:359-379.
21. Guela C., Scatz C.R., Mesulam M.M. Differential localization of NADPH-diaphorase and calbindin-D28k within the cholinergic neurons of the basal forebrain, striatum and brainstem in the rat, monkey, baboon and human. Neuroscience 1993, 54:461-476.
22. Harrison I.F., Bury A., Dexter D.T., Pienaar I.S. Cholinergic cell loss and altered morphology accompanied by structural changes affecting the pedunculopontine nucleus in the lactacystin rat model of Parkinson's disease. Proceedings of the 17th International Congress of Parkinson's disease and Movement disorders 2013, (Abstract # 1033).
23. Heise C.E., Teo Z.C., Wallace B.A., Ashkan K., Benabid A.L., Mitrofanis J. Cell survival patterns in the pedunculopontine tegmental nucleus of methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys and 6-OHDA-lesioned rats: evidence for differences to idiopathic Parkinson disease patients?. Anat. Embryol. 2005, 210:287-302.
24. Herrero M.T., Hirsch E.C., Javoy-Agid F., Obeso J.A., Agid Y. Differential vulnerability to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine of dopaminergic and cholinergic neurons in the monkey mesopontine tegmentum. Brain Res. 1993, 624:281-285.
25. Hirsch E.C., Graybiel A.M., Duyckaerts C., Javoy-Agid F. Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc. Natl. Acad. Sci. U. S. A. 1987, 84:5976-5980.
26. Hobson J.A., Pace-Schott E.F. The cognitive neuroscience of sleep: neuronal systems, consciousness and learning. Nat. Rev. Neurosci. 2002, 3:679-693.
27. Hudson J.L., van Horne C.G., Strömberg I., Brock S., Clayton J., Masserano J., Hoffer B.J., Gerhardt G.A. Correlation of apomorphine- and amphetamine-induced turning with nigrostriatal dopamine content in unilateral 6-hydroxydopamine lesioned rats. Brain Res. 1993, 626:167-174.
28. Iseki E., Kato M., Marui W., Uéda K., Kosaka K. A neuropathological study of the disturbance of the nigro-amygdaloid connections in brains from patients with dementia with Lewy bodies. J. Neurol. Sci. 2001, 185:129-134.
29. Jenkinson N., Nandi D., Aziz T.Z., Stein J.F. Pedunculopontine nucleus: a new target for deep brain stimulation for akinesia. NeuroReport 2005, 16:1875-1876.
30. Jones B.E. Paradoxical sleep and its chemical/structural substrates in the brain. Neuroscience 1991, 40:637-656.
31. Jones T.B., Ankeny D.P., Guan Z., McGaughy V., Fisher L.C., Basso D.M., Popovich P.G. Passive or active immunization with myelin basic protein impairs neurological function and exacerbates neuropathology after spinal cord injury in rats. J. Neurosci. 2004, 24:3752-3761.
32. Karachi C., Grabli D., Bernard F.A., Tandé D., Wattiez N., Belaid H., Bardinet E., Prigent A., Nothacker H.P., Hunot S., et al. Cholinergic mesencephalic neurons are involved in gait and postural disorders in Parkinson disease. J. Clin. Invest. 2010, 120:2745-2754.
33. Lavoie B., Parent A. Pedunculopontine nucleus in the squirrel monkey: cholinergic and glutamatergic projections to the substantia nigra. J. Comp. Neurol. 1994, 344:232-241.
34. Lees A.J. The Parkinson chimera. Neurology 2009, 72(7 Suppl.):S2-S11.
35. Lyons K.E., Pahwa R. The impact and management of nonmotor symptoms of Parkinson's disease. Am. J. Manage Care 2011, 12:S308-S314.
36. Magill P.J., Bolam J.P., Bevan M.D. Dopamine regulates the impact of the cerebral cortex on the subthalamic nucleus-globus pallidus network. Neuroscience 2001, 106:313-330.
37. Marichal N., Garcia G., Radmilovich M., Trujillo-Cenóz O., Russo R.E. Enigmatic central canal contacting cells: immature neurons in "standby mode"?. J. Neurosci. 2009, 29:10010-10024.
38. Martinez-Gonzalez C., Bolam J.P., Mena-Segovia J. Topographical organization of the pedunculopontine nucleus. Front. Neuroanat. 2011, 5:22.
39. Maskos U. The cholinergic mesopontine tegmentum is a relatively neglected nicotinic master modulator of the dopaminergic system: relevance to drugs of abuse and pathology. Br. J. Pharmacol. 2008, 153:S438-S445.
40. Mazzone P., Lozano A., Stanzione P., Galati S., Scarnati E., Peppe A., Stefani A. Implantation of human pedunculopontine nucleus: a safe and clinically relevant target in Parkinson's disease. NeuroReport 2005, 6:1877-1881.
41. McNaught K.S., Olanow C.W. Proteasome inhibitor induced model of Parkinson's disease. Ann. Neurol. 2006, 60:243-247.
42. Mena-Segovia J., Sims H.M., Magill P.J., Bolam J.P. Cholinergic brainstem neurons modulate cortical gamma activity during slow oscillations. J. Physiol. 2008, 586:2947-2960.
43. Mena-Segovia J., Micklem B.R., Nair-Roberts R.G., Ungless M.A., Bolam J.P. GABAergic neuron distribution in the pedunculopontine nucleus defines functional subterritories. J. Comp. Neurol. 2009, 515:397-408.
44. Mesulam M.M., Mufson E.J., Wainer B.H., Levey A.I. Central cholinergic pathways in the rat: an overview based on an alternative nomenclature (Hh1-Ch6). Neuroscience 1983, 10:1185-1201.
45. Mineff E.M., Popratiloff A., Romansky R., Kazakos V., Kaimaktschieff V., Usunoff K.G., Ovtscharoff W., Marani E. Evidence for a possible glycinergic inhibitory neurotransmission in the midbrain and rostral pons of the rat studied by gethyrin. Arch. Physiol. Biochem. 1998, 106:210-220.
46. Mitani A., Ito K., Hallanger A.E., Wainer B.H., Kataoka K., McCarley R.W. Cholinergic projections from the laterodorsal and pedunculopontine tegmental nuclei to the pontine gigantocellular tegmental field in the cat. Brain Res. 1988, 451:397-402.
47. Mitchell I.J., Clarke C.E., Boyce S., Robertson R.G., Peggs D., Sambrook M.A., Crossman A.R. Neural mechanisms underlying Parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Neuroscience 1989, 32:213-226.
48. Mooney S.M., Miller M.W. Post-natal generation of neurons in the ventrobasal nucleus of the rat thalamus. J. Neurosci. 2007, 27:5023-5032.
49. Morfini G.A., Burns M., Binder L.I., Kanaan N.M., LaPointe N., Bosco D.A., et al. Axonal transport defects in neurodegenerative diseases. J. Neurosci. 2009, 29:12776-12786.
50. Moro E., Hamani C., Poon Y.-Y., Al-Khairallah T., Dostrovsky J.O., Hutchison W.D., Lozano A.M. Unilateral pedunculopontine stimulation improves falls in Parkinson's disease. Brain 2010, 133:215-224.
51. Muthusamy K.A., Aravamuthan B.R., Kringelbach M.L., Jenkinson N., Voets N.L., Johansen-Berg H., Stein J.F., Aziz T.Z. Connectivity of the human pedunculopontine nucleus region and diffusion tensor imaging in surgical targeting. J. Neurosurg. 2007, 107:814-820.
52. Oorschot D.E. Total number of neurons in the neostriatal, pallidal, subthalamic, and substantia nigral nuclei of the rat basal ganglia: a stereological study using the cavalieri and optical dissector methods. J. Comp. Neurol. 1996, 366:580-599.
53. Palombo E., Porrino L.J., Bankiewicz K.S., Crane A.M., Sokoloff L., Kopin I.J. Local cerebral glucose utilization in monkeys with hemiparkinsonism induced by intracarotid infusion of the neurotoxin MPTP. J. Neurosci. 1990, 10:860-869.
54. Papahill P.A., Lozano A.M. The pedunculopontine nucleus and Parkinson's disease. Brain 2000, 123:1767-183.
55. Paxinos G., Watson C. The rat brain in stereotaxic coordinates (2nd edition) 1986, Academic Press, New York.
56. Pienaar I.S., Morris C., Burn D., Racca C., Nelson G., Turnbull D.M. Differential mitochondrial protein expression within single glycinergic neurons of the pedunculopontine nucleus of Parkinson's disease patients. Proceedings of the XIXth World Congress on Parkinson's disease and Related Disorders. Parkinsonism Relat. Disord. 2011, 18(Suppl. 1). (abstract # 1.128.).
57. Pienaar I.S., Lu B., Schallert T. Closing the gap between clinic and cage: sensori-motor and cognitive behavioral testing regimens in neutotoxin-induced animal models of Parkinson's disease. Neurosci. Biobehav. Rev. 2012, 36:2305-2324.
58. Plaha P., Gill S.S. Bilateral deep brain stimulation of the pedunculopontine nucleus for Parkinson's disease. NeuroReport 2005, 16:1883-1887.
59. Raff M.C., Whitmore A.V., Finn J.T. Axonal self-destruction and neurodegeneration. Science 2002, 296:868-871.
60. Rinne J.O., Ma S.Y., Lee M.S., Collan Y., Röyttä M. Loss of cholinergic neurons in the pedunculopontine nucleus in Parkinson's disease is related to disability of the patients. Parkinsonism Relat. Disord. 2008, 14:553-557.
61. Rochester L., Yarnall A.J., Baker M.R., David R.V., Lord S., Galna B., Burn D.J. Cholinergic dysfunction contributes to gait disturbance in early Parkinson's disease. Brain 2012, 135:2779-2788.
62. Ros H., Magill P.J., Moss J., Bolam J.P., Mena-Segovia J. Distinct types of non-cholinergic pedunculopontine neurons are differentially modulated during global brain states. Neuroscience 2010, 170:78-91.
63. Rye D.B., Saper C.B., Lee H.J., Wainer B.H. Pedunculopontine tegmental nucleus of the rat: cytoarchitecture, cytochemistry, and some extrapyramidal connections of the mesopontine tegmentum. J. Comp. Neurol. 1987, 259:483-528.
64. Saper C.B., Scammell T.E., Lu J. Hypothalamic regulation of sleep and circadian rhythms. Nature 2005, 437:1257-1263.
65. Scarnati E., Florio T., Capozzo A., Confalone G., Mazzone P. The pedunculopontine tegmental nucleus: implications for a role in modulating spinal cord motorneuron excitability. J. Neural Transm. 2010, 118:1409-1421.
66. Schapira A.H., Jenner P. Etiology and pathogenesis of Parkinson's disease. Mov. Disord. 2011, 26:1049-1055.
67. Schmitz C., Hof P.R. Design-based stereology in neuroscience. Neuroscience 2005, 130:813-831.
68. Schwarting R.K.W., Huston J.P. Unilateral 6-hydroxydopamine lesions of meso-striatal dopamine neurones and their physiological sequelae. Prog. Neurobiol. 1996, 49:215-266.
69. Semba K., Fibiger H.C. Afferent connections of the laterodorsal and the pedunculopontine tegmental nuclei in the rat: a retro- and anterograde transport and immunochemical study. J. Comp. Neurol. 1992, 323:387-410.
70. Steininger T.L., Wainer B.H., Rye D.B. Ultrastructural study of cholinergic and noncholinergic neurons in the pars compacta of the rat pedunculopontine tegmental nucleus. J. Comp. Neurol. 1997, 382:285-301.
71. Sterio D., Berić A., Dogali M., Fazzini E., Alfaro G., Devinsky O. Neurophysiological properties of pallidal neurons in Parkinson's disease. Ann. Neurol. 1994, 35:586-591.
72. Surmeier D.J., Guzman J.N., Sanchez-Padilla J., Goldberg J.A. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Antiox. Redox Signal. 2010, 14:1289-1301.
73. Surmeier D.J., Guzman J.N., Sanchez-Padilla J., Goldberg J.A. What causes the death of dopaminergic neurons in Parkinson's disease?. Prog. Brain Res. 2010, 183:59-77.
74. Takakusaki K., Shiroyama T., Yamamoto T., Kitai S.T. Cholinergic and non-cholinergic tegmental pedunculopontine projection neurons in rats revealed by intracellular labelling. J. Comp. Neurol. 1996, 371:345-361.
75. Topchiy I., Waxman J., Radulovacki M., Carley D.W. Functional topography of respiratory, cardiovascular and pontine-wave responses to glutamate microstimulation of the pedunculopontine tegmentum of the rat. Respir. Physiol. Neurobiol. 2010, 173:64-70.
76. Vernon A.C., Crum W.R., Johansson S.M., Modo M. Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease. PLoS One 2011, 25(6):17269.
77. Vincent S.R. The ascending reticular activating system - from aminergic neurons to nitric oxide. J. Chem. Neuroanat. 2000, 18:23-30.
78. Wang H.L., Morales M. Pedunculopontine and laterodorsal tegmental nuclei contain distinct populations of cholinergic, glutamatergic and GABAergic neurons in the rat. Eur. J. Neurosci. 2009, 29:340-358.
79. West M.J., Slomianka L., Gundersen H.J. Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat. Rec. 1991, 231:482-497.